Full-Time

Marketing Lead Breast & Gyne

Updated on 9/11/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

In Person

Bachelor's, Master's, MBA

Category
Growth & Marketing (1)
Required Skills
Market Research
Product Management
Marketing
Data Analysis

Get referred to Roche

See people who can refer or advise you

Requirements
  • A bachelor's degree in Business Administration, Pharmacy, Marketing, or a related life science discipline.
  • A minimum of 5 years of marketing experience within the pharmaceutical industry or complex healthcare environments, including experience managing multi-product portfolios or high-complexity launches.
  • A minimum of 2 years of hospital market experience in Spain.
  • Experience in functional or direct people management, including coaching, mentoring, and developing strategic capabilities in cross-functional teams.
  • Deep understanding of Spanish hospital market dynamics, market access processes, and field operations.
  • Expertise in leading commercial excellence programs, data analytics tools, advanced marketing metrics, and budget optimization.
  • Experience building strategic partnerships across internal matrix structures and external creative or strategic networks.
  • Fluency in Spanish and English at C1/C2 level.
  • Demonstrated resilience, strategic courage, agility, and a continuous improvement mindset.
Responsibilities
  • Lead the disease-area strategy across all products and indications from a marketing perspective, ensuring cross-squad alignment, strategic coherence, and market impact.
  • Act as the ultimate decision-maker for the marketing function and streamline governance to improve execution speed, agility, and business responsiveness.
  • Lead commercialization excellence initiatives, including advanced segmentation, targeting, market potential modeling, and performance reporting, in alignment with global and local teams.
  • Build, coach, and empower a high-performing marketing team.
  • Drive functional talent development, define capability roadmaps, and build an internal pipeline for future strategic roles.
  • Establish calibration frameworks and objective evaluation metrics to maximize team performance and engagement.
  • Oversee integrated, data-driven omnichannel marketing plans across online and offline channels.
  • Embed digital trends, advanced metrics, and predictive analytics into business decisions.
  • Coordinate with in-field teams and establish relationships with therapeutic area experts and healthcare stakeholders.
  • Direct communication, digital execution, and market research functions to ensure unified brand positioning and customer experience.
  • Represent the affiliate within the international pharmaceutical network and pathology-specific global working groups.
  • Monitor market dynamics, competitive intelligence, and regulatory trends to anticipate disruptions, identify growth opportunities, and mitigate commercial risks.
Desired Qualifications
  • An advanced business degree, such as an MBA or master's degree in Marketing Strategy.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% at constant exchange rates; core profit rose 10%.
  • FDA cleared Elecsys pTau217 on August 24, 2026, unlocking Alzheimer testing at scale.
  • Tam-Peli’s 54% death-risk reduction and global phase III plans strengthen oncology growth.

What critics are saying

  • Biocon’s Perjeta biosimilar lawsuit in New Jersey threatens Herceptin-like erosion by 2027.
  • Genentech disclosed 2026 layoffs, signaling ongoing restructuring and stalled internal productivity.
  • Swiss franc strength cut H1 2026 reported sales 2%, pressuring earnings translation again.

What makes Roche unique

  • Roche’s 4,500 US cobas instruments make Elecsys pTau217 instantly scalable.
  • Roche pairs pharmaceuticals and diagnostics, creating bundled disease franchises competitors cannot match.
  • Genentech gives Roche deep biologics R&D and patented oncology manufacturing depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Yahoo Finance
Sep 1st, 2026
Roche commits $75M upfront in blood cancer deal worth up to $1.53B

Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.

Yahoo Finance
Aug 24th, 2026
Roche and Eli Lilly win FDA clearance for Alzheimer's blood test for over-55s

Roche and Eli Lilly have received FDA clearance for a blood test that helps detect signs of Alzheimer's disease in people aged 55 and older experiencing cognitive decline. The Elecsys pTau217 test measures a blood biomarker to determine whether patients are likely to have brain changes associated with Alzheimer's. The test can be performed using more than 4,500 Roche laboratory analysers already installed across the United States. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, expanding access nationwide. Pricing has not been disclosed. The clearance follows European approval in May. Blood-based testing could provide a simpler alternative to existing methods like PET imaging and cerebrospinal fluid analysis, which can be expensive and invasive.